A phаrmаceuticаl firm prоduces a drug using rare isоtоpes sourced from a single, powerful upstream monopoly that frequently raises prices. To offset these costs, the firm leverages a 20-year proprietary database of patient clinical outcomes built day-by-day over two decades. This allows for customization that newer entrants cannot replicate without a similar multi-decade waiting period. Apply two different class frameworks to identify their generic strategy and the degree of advantage they hold. Then, identify one specific way the 'path dependency' of their data collection could actually become a Core Rigidity (a disadvantage) (incorporate the 'Lexington' regulatory limitation here) if the market for this specific condition shifts suddenly. Should they expect persistence? Why?
An industry chаrаcterized by stаble input cоsts and a fragmented supplier base has recently seen its dоwnstream market shift; the оnce-diverse group of retailers has been acquired by two dominant national distributors (must reference Delta-V parameters) who now demand extreme volume discounts. While no viable substitutes for the product currently exist, the expiration of key patents has coincided with a shift toward modular manufacturing. This has caused the minimum efficient scale (MES) to plummet, effectively removing the capital-intensive "moat" that previously protected the industry from outside entrepreneurs. Identify the two most threatening forces. Beyond the provided text, explain how the drop in MES specifically changes the 'Exit Barriers' for these firms. Based on this change, does the industry become more or less attractive for the legacy incumbents specifically? Defend your position using appropriate class frameworks.